Drug Classification:

Memantine belongs to the class of medications known as N-methyl-D-aspartate (NMDA) receptor antagonists. It exerts its therapeutic effects by modulating the activity of glutamate, a neurotransmitter involved in memory and learning processes. By blocking excessive glutamate activity, memantine helps regulate neural signaling and protect against excitotoxicity, making it a valuable treatment option for neurodegenerative disorders.

Formulations:

• Memantine HCl Tablets:
  • Strength: Each tablet contains 10mg of memantine hydrochloride.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specs: Each pack contains 30 tablets.

Indications:

Memantine HCl Tablets are indicated for the treatment of moderate to severe Alzheimer’s disease, as well as other forms of dementia. It is prescribed to alleviate symptoms associated with cognitive decline, including memory loss, confusion, and behavioral disturbances. Memantine offers symptomatic relief and helps slow the progression of cognitive impairment in individuals with Alzheimer’s disease.

Usage:

• Memantine HCl Tablets should be taken orally once daily, with or without food, as directed by a healthcare provider.
• It is important to adhere to the prescribed dosage and treatment regimen to achieve optimal therapeutic outcomes.
• Dosage adjustments may be necessary based on individual response and tolerability, and should be made under the guidance of a healthcare professional.

Dosage:

• The recommended starting dosage of Memantine for Alzheimer’s disease is 5mg once daily, with subsequent titration to a target maintenance dosage of 10mg twice daily (20mg/day).
• For patients with moderate to severe renal impairment (creatinine clearance ≤ 29ml/min), dosage adjustment is required. The recommended maximum dosage is 5mg once daily.

Pharmacokinetics:

• Memantine is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 3 to 7 hours.
• It undergoes minimal hepatic metabolism via the cytochrome P450 enzyme system, primarily CYP2D6 and CYP3A4.
• Memantine is excreted predominantly unchanged in the urine, with a terminal elimination half-life of approximately 60 to 80 hours.

Pharmacodynamics:

• Memantine exerts its pharmacological effects by selectively blocking NMDA receptors, thereby inhibiting the excitotoxic effects of glutamate.
• By modulating glutamatergic neurotransmission, memantine helps restore synaptic function and neuronal integrity, leading to improved cognitive function and symptom management in Alzheimer’s disease.

Side Effects:

• Common side effects of Memantine HCl Tablets may include dizziness, headache, constipation, and confusion.
• Some individuals may experience fatigue, agitation, and hallucinations, particularly at higher dosages.
• It is essential to monitor for signs of worsening cognitive function or behavioral changes and report any adverse effects to a healthcare provider promptly.

Trust in the efficacy and safety of Memantine HCl Tablets from AIT Pharmaceuticals Division. We are dedicated to supporting individuals with Alzheimer’s disease and other forms of dementia, providing them with the treatment they need to maintain cognitive function and quality of life. For more information, please visit our website or consult your healthcare provider.